Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Ainura Mussakulova, Zarina Zhalgasbaeva, Vyacheslav Korobeynikov, Gulnur Zhunussova
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota
1994
The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the management of thyroid eye disease
10.1530/eje-21-0479 · 2021
Federal clinical recommendations on diagnostics and treatment of endocrine ophthalmopathy associated with autoimmune thyroid pathology
10.14341/probl201561161-74 · 2015
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): A randomised, observer-masked, multicentre trial
10.1016/s2213-8587(18)30020-2 · 2018
10.3390/life12122084
10.3390/life12122084
Teprotumumab: A Review in Thyroid Eye Disease
10.1007/s40265-022-01804-1 · 2022
TSH receptor autoantibody levels post-total thyroidectomy in Graves’ ophthalmopathy: A meta-analysis
10.1007/s00423-023-03153-3 · 2023
10.1186/s12893-025-03081-7
10.1186/s12893-025-03081-7
Graves’ orbitopathy: Imperfect treatments for a rare disease
10.1159/000356042 · 2013
Risk factors for development or deterioration of Graves’ ophthalmopathy
10.1089/thy.2010.1634 · 2010
Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy
10.3349/ymj.2015.56.5.1389 · 2015
IL-17 and IL-38 gene polymorphisms in thyroid-associated ophthalmopathy
10.1007/s10792-024-03317-0 · 2024
Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy
10.1016/j.xcrm.2022.100699 · 2022
Transcriptomic profiling of control and thyroid-associated orbitopathy (TAO) orbital fat and TAO orbital fibroblasts undergoing adipogenesis
10.1167/iovs.62.9.24 · 2021
Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway
10.1172/jci.insight.182352 · 2024
PDGFRα+DPP4+ Fibroblasts-Macrophage Crosstalk Induces Orbital Fibrosis in Treatment-Resistant Thyroid Eye Disease via the GAS6-AXL Pathway
10.1002/advs.202511404 · 2025
Bulk and single-cell transcriptomic profiling identifies C1QA as an immune-associated hub gene in graves’ ophthalmopathy
10.1007/s12020-025-04426-1 · 2025
Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease
10.1016/j.beem.2011.10.005 · 2012
Single-Cell Landscape of Peripheral Blood Mononuclear Cells in Patients with Graves Disease
10.1210/endocr/bqaf038 · 2025
Assessment of the levels of interleukin-17 and interleukin-38 in thyroid-associated ophthalmopathy patients
10.1007/s10792-023-02679-1 · 2023
Bioassays for TSH Receptor Antibodies: Quo Vadis?
10.1159/000375445 · 2015
Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy
10.1038/s41433-018-0315-9 · 2019
Intersection of Chemokine and TSH Receptor Pathways in Human Fibrocytes: Emergence of CXCL-12/CXCR4 Cross Talk Potentially Relevant to Thyroid-Associated Ophthalmopathy
10.1210/en.2016-1382 · 2016
TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile
10.1073/pnas.1821565116 · 2019
10.3389/fimmu.2022.804401
10.3389/fimmu.2022.804401
The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves’ Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis
10.1210/clinem/dgae711 · 2025
Efficacy and safety of Tocilizumab for thyroid eye disease: A systemic review and Meta-analysis
10.1007/s40618-025-02595-4 · 2025
JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases
10.1016/j.revmed.2024.10.452 · 2025
JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases
10.1016/j.revmed.2024.10.452 · doi-reference
Efficacy and safety of Tocilizumab for thyroid eye disease: A systemic review and Meta-analysis
10.1007/s40618-025-02595-4 · doi-reference
The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves’ Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis
10.1210/clinem/dgae711 · doi-reference
10.3389/fimmu.2022.804401
10.3389/fimmu.2022.804401 · doi-reference
TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile
10.1073/pnas.1821565116 · doi-reference
Intersection of Chemokine and TSH Receptor Pathways in Human Fibrocytes: Emergence of CXCL-12/CXCR4 Cross Talk Potentially Relevant to Thyroid-Associated Ophthalmopathy
10.1210/en.2016-1382 · doi-reference
Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy
10.1038/s41433-018-0315-9 · doi-reference
Bioassays for TSH Receptor Antibodies: Quo Vadis?
10.1159/000375445 · doi-reference
Assessment of the levels of interleukin-17 and interleukin-38 in thyroid-associated ophthalmopathy patients
10.1007/s10792-023-02679-1 · doi-reference
Single-Cell Landscape of Peripheral Blood Mononuclear Cells in Patients with Graves Disease
10.1210/endocr/bqaf038 · doi-reference
Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease
10.1016/j.beem.2011.10.005 · doi-reference
Bulk and single-cell transcriptomic profiling identifies C1QA as an immune-associated hub gene in graves’ ophthalmopathy
10.1007/s12020-025-04426-1 · doi-reference
PDGFRα+DPP4+ Fibroblasts-Macrophage Crosstalk Induces Orbital Fibrosis in Treatment-Resistant Thyroid Eye Disease via the GAS6-AXL Pathway
10.1002/advs.202511404 · doi-reference
Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway
10.1172/jci.insight.182352 · doi-reference
Transcriptomic profiling of control and thyroid-associated orbitopathy (TAO) orbital fat and TAO orbital fibroblasts undergoing adipogenesis
10.1167/iovs.62.9.24 · doi-reference
Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy
10.1016/j.xcrm.2022.100699 · doi-reference
IL-17 and IL-38 gene polymorphisms in thyroid-associated ophthalmopathy
10.1007/s10792-024-03317-0 · doi-reference
Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy
10.3349/ymj.2015.56.5.1389 · doi-reference
Graves’ orbitopathy: Imperfect treatments for a rare disease
10.1159/000356042 · doi-reference
10.1186/s12893-025-03081-7
10.1186/s12893-025-03081-7 · doi-reference
TSH receptor autoantibody levels post-total thyroidectomy in Graves’ ophthalmopathy: A meta-analysis
10.1007/s00423-023-03153-3 · doi-reference
Teprotumumab: A Review in Thyroid Eye Disease
10.1007/s40265-022-01804-1 · doi-reference
10.3390/life12122084
10.3390/life12122084 · doi-reference
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): A randomised, observer-masked, multicentre trial
10.1016/s2213-8587(18)30020-2 · doi-reference
Federal clinical recommendations on diagnostics and treatment of endocrine ophthalmopathy associated with autoimmune thyroid pathology
10.14341/probl201561161-74 · doi-reference
The 2021 European Group on Graves’ Orbitopathy (EUGOGO) clinical practice guidelines for the management of thyroid eye disease
10.1530/eje-21-0479 · doi-reference
Risk factors for development or deterioration of Graves’ ophthalmopathy
10.1089/thy.2010.1634 · doi-reference